Studies radiotherapy for a few spread cancers, guided by patient data
Observes patients with limited spread of cancer treated with stereotactic radiotherapy.
Plain-language title generated from the registry record
Registry title: The Impact of Radiotherapy on Oligometastatic Cancer
Key facts
- Where
- Albacete, Barcelona, Castellon, Girona, Granada, Lleida, Madrid, Reus, Seville, Terrassa, Valencia, and Zaragoza, SpainSee the 21 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with breast, prostate, lung or colorectal cancer that has spread to up to five places in the body, and who are in good physical shape.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Up to five metastases in the bone, lung, lymph node, liver or brain. Primary tumor confirmed as breast, prostate, lung or colorectal.
- Earlier treatment
- No previous radiotherapy in the same body area.
Main reasons for not taking part
- Non-melanoma skin cancer
- Previous radiotherapy in the same body area
- Vascular collagen disease
- Pregnancy or breastfeeding at the time of joining
Read by machine on 12 November 2026.
Where in Spain
- Complejo Hospitalario Universitario AlbaceteAlbacete, SpainContact: Sebastià SabaterNot yet recruiting
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauBarcelona, SpainContact: Jady Vivian RojasNot yet recruiting
- Hospital del MarBarcelona, SpainContact: Ismael MembriveNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainContact: Victoria ReyesNot yet recruiting
- Institut Catala d'OncologiaBarcelona, SpainContact: Evelyn MartínezNot yet recruiting
- Hospital Provincial de CastellónCastellon, SpainContact: Carlos FerrerNot yet recruiting
- Institut Català d'OncologiaGirona, SpainContact: Arancha ErasoNot yet recruiting
- Hospital Universitario Virgen de las NievesGranada, SpainContact: Rosario Del MoralNot yet recruiting
- Hospital Universitari Arnau de VilanovaLleida, SpainContact: Moisés MiraNot yet recruiting
- Hospital de La LuzMadrid, SpainContact: Sofía SanchezNot yet recruiting
- Hospital Ruber InternacionalMadrid, SpainContact: Aurora RodríguezNot yet recruiting
- Hospital Universitario HM SanchinarroMadrid, SpainContact: Ángel MonteroNot yet recruiting
- Hospital Universitario QuirónsaludMadrid, SpainContact: Elia Del CerroNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainContact: Eva FernándezNot yet recruiting
- Hospital Universitario Rey Juan CarlosMadrid, SpainContact: Stephanyie PayanoNot yet recruiting
- Hospital Universitari Sant Joan de ReusReus, SpainContact: Jorge Joven, Prof.Taking people
- Hospital Universitario Virgen MacarenaSeville, SpainContact: Carlos MíguezNot yet recruiting
- Hospital de TerrassaTerrassa, SpainContact: Josep Maria SoléNot yet recruiting
- Hospital Clinico Universitario de ValenciaValencia, SpainContact: Ester JordàNot yet recruiting
- Hospital General Univesitario de ValenciaValencia, SpainContact: Amparo GonzálezNot yet recruiting
- Hospital Universitari Miguel ServetZaragoza, SpainContact: Reyes IbáñezNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institut Investigacio Sanitaria Pere Virgili
- Trial code
- NCT05933876
- Record updated
- 18 November 2024
- Original description
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.Read full original descriptionShow less
Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Inclusion: Histologic confirmation of primary tumor: breast, prostate, lung, colorectal; 18 years old or older; Up to five metastases located in the bone, lung, node, liver or brain; Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.
Exclusion: Previous radiotherapy in the same anatomic location; Non-melanoma skin cancer; Presence of vascular collagen disease; Pregnancy or lactation at the time of inclusion.